Formulation Development
Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin-Based Adjuvants for Life-Saving Vaccines
Q-VANT Biosciences has launched as the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants including QS-21. QS-21 is considered the “Gold Standard” adjuvant for enhancing immune….
HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia
HUTCHMED (China) Limited recently announced the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to HMPL-523,…
COVAXIN (BBV152) Booster Shown to Neutralize Both Omicron & Delta Variants of SARS-CoV-2
Ocugen, Inc.and its partner, Bharat Biotech recently announced results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of candidate vaccine….
atai Life Sciences Announces FDA IND Clearance for PCN-101 R-ketamine Program
atai Life Sciences N.V. recently announced the US FDA has given Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R-ketamine). atai plans to initiate the….
Zai Lab Announces First Patient Treated in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer
Zai Lab Limited recently announced treatment of the first patient in Greater China in the PANOVA-3 trial, a Phase 3 pivotal trial of Tumor Treating…
Definitive Agreement to Acquire Exelead Will Strengthen the CDMO Offering for mRNA of the Life Science Business of Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany recently announced the signing of a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately…
SK Inc., the Second Largest Conglomerate in South Korea, Has Invested $350 Million in the Center for Breakthrough Medicines
The Center for Breakthrough Medicines recently announced it has received $350 million in equity financing from SK Inc.. CBM is partnering with SK to create…
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
Sana Biotechnology, Inc., IASO Biotherapeutics, and Innovent Biologics recently announced the companies entered into an agreement pursuant to which Sana obtained from IASO Bio and Innovent non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct for use in certain….
NeoCura & PhoreMost Announce Research Collaboration to Explore Novel Cancer Therapeutics
NeoCura Bio-Medical Technology Co., Ltd. and PhoreMost Limited recently announced an oncology drug discovery research collaboration. As part of the collaboration, PhoreMost’s SITESEEKER phenotypic screening platform and NeoCura’s full-process RNA drug design platform will….
Black Diamond Therapeutics Announces FDA Allowance of IND Application for a MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma & Non-Small Cell Lung Cancer
Black Diamond Therapeutics, Inc. recently announced the US FDA has cleared an investigational new drug (IND) application for its MasterKey inhibitor BDTX-1535, an irreversible, mutant…
Harpoon Therapeutics Provides Pipeline Development Milestones for 2022
Harpoon Therapeutics, Inc. recently provided a pipeline milestone update on its TriTAC development programs. “We are excited to begin 2022 with a catalyst rich year…
Quris Closes $28 Million in Seed Funding From Top Institutional Investors
Quris recently announced the final close of $28 million in seed funding – inclusive of the initial $9 million announced late last year with the launch…
Malvern Panalytical Expands Pharmaceutical Drug Development Solutions Through Acquisition of Creoptix
Malvern Panalytical recently announced its acquisition of Creoptix AG, a specialist bioanalysis sensor company. The acquisition forms a critical part of Malvern Panalytical’s strategy to….
Emerald Health Pharmaceuticals Receives IND Clearance to Begin Phase 2 Clinical Trial of EHP-101 for Relapsing Forms of Multiple Sclerosis
Emerald Health Pharmaceuticals Inc. has received clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to begin enrolling…
PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy
PDS Biotechnology Corporation recently announced it has been granted US Patent Application No. 15,724,818 titled Novel HPV16 Non HLA-Restricted T-cell Vaccines, Composition and Methods of…
BioNTech & Crescendo Biologics Announce Global Collaboration to Develop Multi-Specific Precision Immunotherapies
BioNTech SE and Crescendo Biologics Ltd. recently announced they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer…
Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors
Fate Therapeutics, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen…
4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis Pigmentosa
4D Molecular Therapeutics recently announced the US FDA has granted Fast Track Designation for 4D-125 for treatment of patients with inherited retinal dystrophies due to defects in….
Starton Therapeutics Receives Clinical Trial Authorization in Europe to Initiate Phase 1 Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide
Starton Therapeutics Inc. recently announced it has received a Clinical Trial Authorization (CTA) in the Netherlands to initiate a Phase 1 study evaluating STAR-LLD bioavailability in….
Wheeler Bio Announces $14-Million Seed Round to Expand Access to Portable CMC
Wheeler Bio, a biomanufacturing company built to accelerate the translation of therapeutic innovation into clinical impact, recently announced the closing of a $14-million Seed financing…
